度洛西汀联合心脑宁胶囊对晚发性抑郁的疗效观察
本文选题:度洛西汀 + 心脑宁胶囊 ; 参考:《兰州大学》2017年硕士论文
【摘要】:目的:观察度洛西汀及心脑宁胶囊联合用药对晚发性抑郁患者认知功能的作用和临床疗效。方法:根据入组排除标准选2015年8月-2016年12月兰州大学第二医院门诊或住院晚发性抑郁症患者70例(病例组),限制性随机分组分联合组(度洛西汀联合心脑宁胶囊)和西药组(度洛西汀),治疗前与治疗第2、4、8、12周末采用汉密尔顿抑郁量表(HAMD-24)评定抑郁程度及药物副反应量表评定不良反应;治疗前与治疗第12周末进行认知功能测评(数字广度、无意义图形再认、连线测试、数字符号、威斯康星卡片分类测验、字色干扰试验、词汇流畅性测验)和日常生活能力量表测评。根据入组标准选50例健康老年人(正常对照组)进行认知功能和日常生活能力测评。比较治疗前病例组与正常对照组认知功能和日常生活能力;比较联合组与西药组疗效、对认知功能的作用和不良反应;比较治疗后联合组与正常对照组认知功能和日常生活能力。结果:1.治疗前病例组在数字广度-顺背、无意义图形再认、数字符号、数字广度-倒背、WCST完成分类数、stroop-c、stroop-cw、词汇流畅性测验等认知功能相关测试评分均低于正常对照组,差异有统计学意义(P0.01);WCST随机错误数、WCST持续错误数、连线测试A、连线测试B、ADL评分均高于正常对照组,差异有统计学意义(P0.01)。2.HAMD24评分重复测量方差分析结果显示:组间和组内差异均有统计学意义(P0.05或P0.01);时间与分组无交互作用(P0.05)。组间各时间点比较,治疗第2、4周末联合组与西药组HAMD24评分差异无统计学意义(P0.05),治疗第8、12周末联合组HAMD24评分低于西药组,差异有统计学意义(P0.05)。联合组有效率高于西药组(91.43%vs.71.43%),差异有统计学意义(P0.05),痊愈率(28.57%vs.20.00%)差异无统计学意义(P0.05)。3.治疗第12周末,组内比较,联合组数字广度-顺背、无意义图形再认、数字符号、数字广度-倒背、WCST完成分类数、stroop-c、stroop-cw、词汇流畅性测验评分均高于治疗前,WCST随机错误数、WCST持续错误数、连线测试A、连线测试B、ADL评分均低于治疗前,差异显著(P0.01);西药组数字广度-顺背、无意义图形再认、数字符号、数字广度-倒背评分均高于治疗前,连线测试A、连线测试B、ADL评分低于治疗前,差异显著(P0.01),WCST完成分类数、WCST随机错误数、WCST持续错误数、stroop-c、stroop-cw、词汇流畅性测验评分与治疗前相比,差异无统计学意义(P0.05)。治疗第12周末,组间比较,联合组数字符号、数字广度-倒背、WCST完成分类数、stroop-c、stroop-cw、词汇流畅性测验评分均高于西药组,WCST随机错误数、WCST持续错误数、连线测试B、ADL评分低于西药组,差异有统计学意义(P0.05或P0.01),数字广度-顺背、无意义图形再认、连线测试A与西药组比较,差异无统计学意义(P0.05)。4.治疗第12周末,联合组数字广度-顺背、无意义图形再认、数字广度-倒背、WCST完成分类数、stroop-c、stroop-cw、词汇流畅性测验评分均低于正常对照组,连线测试A、WCST随机错误数、WCST持续错误数、连线测试B、ADL评分均高于正常对照组,差异有统计学意义(P0.01或P0.05);联合组数字符号评分与正常对照组差异无统计学意义(P0.05)。5.联合组与西药组不良反应事件发生频率差异无统计学意义(χ2=0.467,P0.05)。结论:1.晚发性抑郁患者存在短时记忆、注意、执行功能等认知功能障碍。2.度洛西汀联合心脑宁胶囊与单用度洛西汀治疗晚发性抑郁均有效,安全性均好。3.联合心脑宁胶囊比单用度洛西汀治疗LOD的抗抑郁疗效更显著,对持续性注意、注意的转换功能和执行功能方面认知损害的改善作用更明显。
[Abstract]:Objective: To observe the effect and clinical effect of duloxetine and Xin nnning Capsule on the cognitive function of patients with late onset depression. Methods: according to the exclusion criteria, 70 cases of late onset depression in Second Hospital Affiliated to Lanzhou University in August 2015, December, -2016 (case group), restricted randomized grouping combined group (duloxi) Tine and Xin nnning capsule) and Western medicine group (duloxetine), before and after treatment for 2,4,8,12 weekend, the Hamilton Depression Scale (HAMD-24) was used to assess the depressive degree and drug side reaction scale to assess the adverse reaction. The cognitive function assessment (Digital breadth, meaningless graphic recognition, connection test, digital character) before and twelfth weekend treatment was evaluated. Number, Wisconsin card classification test, word color interference test, vocabulary fluency test, and daily living capacity scale assessment. The cognitive function and daily living ability of 50 healthy elderly people (normal control group) were selected according to the standard of entry group. The cognitive function and daily living ability of the pre treatment and normal control group were compared. The effect of combination group and Western Medicine Group on cognitive function and adverse reaction; compare the cognitive function and daily life ability of the combined group and the normal control group after treatment. Results: 1. before treatment, the case group was in the digital breadth - CIS back, no meaningful graphic recognition, digital symbols, digital breadth - back, WCST complete classification, stroop-c, stroop-cw, fluency of vocabulary. The score of cognitive function test, such as sex test, was lower than that of the normal control group, and the difference was statistically significant (P0.01); the WCST random error number, the WCST continuous error number, the connection test A, the connection test B, and the ADL score were all higher than those of the normal control group, the difference was statistically significant (P0.01) and the results of the repeated measurement of variance analysis of.2.HAMD24 score showed: in group and in group The difference was statistically significant (P0.05 or P0.01); there was no interaction between time and group (P0.05). There was no significant difference in the HAMD24 score between the combination group and the western medicine group at the end of the group 2,4 weekend (P0.05). The HAMD24 score of the combined group was lower than that in the western medicine group (P0.05). The effective rate of the combined group was high. In the western medicine group (91.43%vs.71.43%), the difference was statistically significant (P0.05), and the difference in recovery rate (28.57%vs.20.00%) was not statistically significant (P0.05) for the twelfth weekend of.3. treatment. In the group, the combined group digital breadth - CIS back, no meaningful graphic recognition, digital symbols, digital breadth - back, WCST complete classification, stroop-c, stroop-cw, vocabulary fluency test The scores were all higher than before the treatment, WCST random error number, WCST continuous error number, line test A, line test B, ADL score were lower than before treatment, the difference was significant (P0.01); the western medicine group digital breadth - CIS back, no meaningful graphic recognition, digital symbol, digital breadth - back score were higher than before treatment, connection test A, connection test B, ADL score below treatment Before, the difference was significant (P0.01), the number of WCST completed, the number of WCST random errors, the number of WCST continuous errors, stroop-c, stroop-cw, and the vocabulary fluency test score was not statistically significant (P0.05). The twelfth weekend, the group comparison, the combined group digital symbols, the digital breadth back, the WCST complete classification, stroop-c, stroop-cw, and the vocabulary. The fluency test scores were higher than the western medicine group, the WCST random error number, the WCST continuous error number, the connection test B, and the ADL score lower than the western medicine group, the difference was statistically significant (P0.05 or P0.01), the digital breadth - CIS back, the non sense graphic recognition, the connection test A and the western medicine group, the difference was not statistically significant (P0.05).4. treatment twelfth weekend, the combined group number Word breadth - CIS back, nonsense graphic recognition, digital breadth - back, WCST complete classification, stroop-c, stroop-cw, the vocabulary fluency test scores were lower than the normal control group, the line test A, the WCST random error number, the WCST continuous error number, the connection test B, the ADL score higher than the normal control group, the difference was statistically significant (P0.01 or P0.05); the difference was statistically significant (P0.01 or P0.05); the difference was statistically significant (P0.01 or P0.05); the statistical significance was statistically significant (P0.01 or P0.05); the statistical significance was statistically significant There was no significant difference between the score of group digital symbols and the normal control group (P0.05) there was no significant difference in the frequency of adverse events between the.5. combined group and the western medicine group (x 2=0.467, P0.05). Conclusion: 1. the patients with late onset depression have short time memory, attention, executive function and other cognitive dysfunction.2. degrees luoxetine combined heart NanNin capsule and single The use of luoxetine is effective in the treatment of late onset depression. The safety of.3. combined with cardio NanNin capsule is more significant than that of single use luoxetine in the treatment of LOD. It is more significant for the improvement of cognitive impairment in continuous attention, attention to conversion and executive function.
【学位授予单位】:兰州大学
【学位级别】:硕士
【学位授予年份】:2017
【分类号】:R749.4
【相似文献】
相关期刊论文 前10条
1 李晓东;度洛西汀将填补氟西汀专利期满留下的空白[J];国外医药(合成药 生化药 制剂分册);2002年06期
2 徐娟;度洛西汀有可能替代氟西汀成为抗抑郁畅销药[J];国外医学.药学分册;2002年06期
3 黄美珍;潘学武;曾为群;谢玲;;度洛西汀对持续性躯体形式疼痛障碍的作用[J];中国生化药物杂志;2010年01期
4 伍建红;;氟西汀、度洛西汀治疗持续性躯体形式疼痛障碍的对照研究[J];中外医学研究;2012年31期
5 常丽艳;金桂娟;高凤玖;;度洛西汀治疗癌症后抑郁的临床研究[J];中国民康医学;2013年15期
6 赵永忠;王维千;陈宏;;度洛西汀治疗持续性躯体形式疼痛障碍的临床观察[J];临床精神医学杂志;2014年01期
7 ;礼来公司的度洛西汀用于尿失禁治疗[J];世界临床药物;2003年10期
8 赵静,朱珠;度洛西汀临床应用的安全性[J];药物不良反应杂志;2005年04期
9 邵仲英;徐巧玲;史爱欣;;新型5-羟色胺和去甲肾上腺素再摄取抑制剂——度洛西汀[J];中国全科医学;2006年10期
10 国效峰;赵靖平;陈晋东;;度洛西汀:一种新型抗抑郁药[J];中国新药与临床杂志;2006年07期
相关会议论文 前10条
1 朱毅平;钱敏才;金学敏;徐哲;;度洛西汀与氟西汀治疗抑郁伴随疼痛的对照研究[A];浙江省医师协会精神科医师分会成立大会暨二○○八年浙江省精神病学学术年会论文汇编[C];2008年
2 陈德沈;陈远岭;;度洛西汀与氟西汀治疗抑郁症对照研究[A];2009年浙江省医学会精神病学学术年会暨浙江省医师协会精神科医师分会第二届年会论文汇编[C];2009年
3 李俊丽;温祁;马向芹;于培明;;抗抑郁药度洛西汀专利现状分析[A];2013年中国药学会药事管理专业委员会年会暨“医药安全与科学发展”学术论坛论文集(上册)[C];2013年
4 王洪飞;罗忠;郑学宝;李金亮;徐守艳;;度洛西汀结合认知疗法对产后抑郁的疗效观察[A];第七届全国心理卫生学术大会论文汇编[C];2014年
5 沈鑫华;钱敏才;林敏;费小聪;王士良;;度洛西汀和舍曲林治疗抑郁症的对照研究[A];浙江省医师协会精神科医师分会成立大会暨二○○八年浙江省精神病学学术年会论文汇编[C];2008年
6 应益飞;叶剑辉;;度洛西汀与氟西汀治疗抑郁症临床对照观察[A];2011年浙江省心身医学学术年会论文汇编[C];2011年
7 王文;董玉琳;张婷;王莉颖;白璐;夏亮;武胜昔;李云庆;;度洛西汀通过抑制杏仁核神经元活化减弱皮下注射福尔马林诱导的机械性痛敏[A];中国解剖学会2012年年会论文文摘汇编[C];2012年
8 陈文斌;汪孝岩;范爱月;;度洛西汀治疗脑梗死后抑郁的临床观察[A];2012年浙江省神经病学学术年会论文集[C];2012年
9 王洪飞;蒋静珠;李金亮;郑学宝;罗忠;徐守艳;;度洛西汀结合认知疗法对产后抑郁的疗效观察[A];2013浙江省医学会精神病学分会学术年会暨浙江省医师协会精神科医师分会第六届年会论文汇编[C];2013年
10 司马蕾;樊碧发;闫龙涛;水源;;普瑞巴林和度洛西汀单药或联合用药治疗神经病理性癌痛的随机对照平行研究[A];中国肿瘤内科进展 中国肿瘤医师教育(2014)[C];2014年
相关重要报纸文章 前9条
1 庄瑜;抑郁症治疗新药度洛西汀[N];中国医药报;2004年
2 河北省邢台市第二医院 刘文山;度洛西汀慎用于慢肝病人[N];大众卫生报;2005年
3 本报特约撰稿人 黄东临;度洛西汀:希望在明天[N];医药经济报;2004年
4 ;礼来收益持续攀高[N];医药经济报;2004年
5 芝平;度洛西汀——SUI治疗新希望[N];中国医药报;2003年
6 国讯;澳大利亚警示度洛西汀引起五羟色胺综合征的风险[N];中国医药报;2014年
7 本报特约撰稿人 栾雪梅;百优解垮了,,礼来岂能善罢甘休[N];医药经济报;2003年
8 余志平;减少疼痛 新药物初显光芒[N];中国医药报;2004年
9 徐轩;药企大佬觊觎抗抑郁市场[N];医药经济报;2014年
相关硕士学位论文 前10条
1 张珊珊;度洛西汀联合心脑宁胶囊对晚发性抑郁的疗效观察[D];兰州大学;2017年
2 王士良;情感障碍家族史对度洛西汀治疗抑郁症效果的影响研究[D];浙江大学;2015年
3 刘兴兰;度洛西汀治疗抑郁障碍的剂量、血药浓度与疗效、副反应的相关性研究[D];昆明医科大学;2015年
4 刘海林;度洛西汀治疗广泛性焦虑障碍的疗效和安全性的meta分析[D];重庆医科大学;2015年
5 朱柯彪;抗抑郁药度洛西汀中间体的合成研究[D];武汉工程大学;2016年
6 郭磊;度洛西汀及其衍生物的合成研究[D];河北工业大学;2010年
7 郭莉娜;度洛西汀及达泊西汀的合成研究[D];华中师范大学;2007年
8 沈云霞;度洛西汀中间体手性醇的生物转化[D];扬州大学;2009年
9 白春梅;度洛西汀和托莫西汀的合成工艺研究[D];华东师范大学;2011年
10 王健;度洛西汀及其修饰物的合成研究[D];天津大学;2006年
本文编号:2051029
本文链接:https://www.wllwen.com/yixuelunwen/jsb/2051029.html